Peripheral T-Cell Lymphoma (PTCL) Market Insights, Epidemiology, and Forecast, 2026-2036 | 7MM Market to Double to $1.6 Billion as Targeted Therapies Drive 7% CAGR
Dublin, Oct. 15, 2026 (GLOBE NEWSWIRE) -- "Peripheral T-Cell Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The peripheral T-cell lymphoma (PTCL) market across the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan was valued at approximately USD 800 million in 2025. According to the report, the market is projected to reach approximately USD 1.60 billion by 2036, expanding at a CAGR of about 7% during 2026-2036.
Market growth will be supported by improved disease recognition, wider use of molecular diagnostics, increasing PTCL incidence, and the advancement of targeted therapies for newly diagnosed and relapsed/refractory (R/R) disease. However, poor prognosis, high relapse rates, treatment toxicity, and limited durable responses continue to create significant unmet medical needs.
PTCL Epidemiology and Patient Burden
PTCL represents a rare and heterogeneous group of aggressive T-cell malignancies. It accounts for approximately 10-15% of non-Hodgkin lymphomas in the United States, 6.5% in Europe, and 25% in Japan. PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL) are among the most frequently diagnosed subtypes.
Improved pathology standards and molecular testing are reducing historical underdiagnosis and enabling more accurate subtype classification. Aging populations, immune dysregulation, autoimmune disease, HIV, and post-transplant immunosuppression are also contributing to the expanding high-risk patient pool.
Current PTCL Treatment Landscape
First-line PTCL treatment continues to rely primarily on anthracycline-based chemotherapy. CHOP remains widely used for CD30-negative disease, while ADCETRIS combined with CHP has become an important option for CD30-positive PTCL, particularly systemic ALCL. Eligible patients may receive autologous stem cell transplantation as consolidation after first remission.
Despite its established role, first-line chemotherapy frequently fails to produce durable remission. Patients who cannot tolerate cytotoxic chemotherapy have particularly limited options. Previous efforts to improve CHOP through combination strategies have often been constrained by increased toxicity and insufficient biologically guided patient selection.
Approved and subtype-specific treatments include ADCETRIS, BELEODAQ, POTELIGEO, XALKORI, EZHARMIA, FOLOTYN, and other agents used according to disease characteristics, treatment history, and regional availability. Japan remains a major center for PTCL therapy approvals, reflecting its regulatory activity and focus on rare T-cell malignancies.
In 2025, ADCETRIS generated more than USD 300 million across the leading markets and held the largest PTCL market share. Nevertheless, variability in CD30 expression and differences in clinical benefit across PTCL subtypes continue to influence treatment selection.
Emerging PTCL Pipeline and Competitive Landscape
The PTCL pipeline is increasingly focused on biomarker-aligned and targeted therapies. Leading investigational assets include lacutamab from Innate Pharma, soquelitinib from Corvus Pharmaceuticals, golidocitinib from Dizal Pharmaceutical, linperlisib from Shanghai YingLi Pharmaceutical, and duvelisib from Secura Bio.
Several emerging therapies are being evaluated for second-line use, including duvelisib, tolinapant with or without ASTX727, golidocitinib, lacutamab, and sugemalimab. Golidocitinib may be among the earliest of these candidates to enter the market, potentially by 2027. New launches are expected to increase competition in the R/R setting and place pressure on the market share of established therapies.
Key companies active in the PTCL market include Pfizer, Kyowa Kirin, Citius Pharmaceuticals, Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceutical, Corvus Pharmaceuticals, Daiichi Sankyo, Takeda, Innate Pharma, and Acrotech BioPharma.
Market Outlook and Commercial Opportunities
The United States is forecast to account for approximately 68% of the PTCL market by 2036. Future commercial performance will depend on differentiated efficacy, manageable safety, biomarker-supported positioning, broad subtype applicability, and scalable market access strategies.
Pricing, reimbursement, and cost-effectiveness will remain critical to therapy adoption. For example, FOLOTYN has an estimated treatment cost of approximately USD 745,785 based on its recommended dosing schedule and an approximate price of USD 6,780 per 20 mg vial. As additional high-cost therapies enter the market, payers are expected to increase their focus on clinical value and alternative payment models.
Persistent Unmet Needs
The report provides epidemiology forecasts, historical and projected market sizing, therapy uptake analysis, pricing and reimbursement insights, competitive intelligence, SWOT and conjoint analysis, and profiles of approved and emerging PTCL therapies. It also incorporates perspectives from more than 10 key opinion leaders and subject matter experts affiliated with leading clinical and academic institutions.
With multiple mid-stage and late-stage assets progressing through clinical development, the PTCL treatment market is entering a period of increasing innovation. Therapies demonstrating clear clinical differentiation, durable responses, acceptable safety, and precise biomarker positioning are expected to be best placed to capture future market opportunities.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Upcoming Key Catalysts
4.2. New flow
4.3. Data Presentation
4.4. Key Transactions and Collaborations
5. Epidemiology and Market Forecast Methodology
6. Peripheral T-cell lymphoma (PTCL) Market Overview at a Glance
6.1. Market Landscape Analysis (By Molecule Type, Route of Administration [RoA], and Mechanism of action [MoA])
6.2. Emerging Landscape Analysis (by Molecule Type, Phase, and Route of Administration [RoA])
6.3. Market Share of Peripheral T-cell lymphoma (PTCL) by Therapies (%) in the 7MM in 2025
6.4. Market Share of Peripheral T-cell lymphoma (PTCL) by Therapies (%) in the 7MM in 2036
7. Disease Background and Overview of Peripheral T-cell lymphoma (PTCL)
7.1. Introduction
7.2. Causes and Risk Factors
7.3. Signs and Symptoms
7.4. Pathophysiology
7.5. Diagnosis of Peripheral T-cell lymphoma (PTCL)
8. Epidemiology and Patient Population of Peripheral T-cell lymphoma (PTCL)
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Total Incident Cases of Peripheral T-cell lymphoma (PTCL) in the 7MM
8.4. The United States
8.4.1. Total Incident cases of Peripheral T-cell lymphoma (PTCL) in the US
8.4.2. Stage-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in the US
8.4.3. Type-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in the US
8.4.4. CD30 Expression-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in the US
8.4.5. Line-wise Treated Cases of Peripheral T-cell lymphoma (PTCL) in the US
8.5. EU4 and the UK
8.5.1. Total Incident cases of Peripheral T-cell lymphoma (PTCL) in EU4 and the UK
8.5.2. Stage-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in EU4 and the UK
8.5.3. Type-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in EU4 and the UK
8.5.4. CD30 Expression-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in EU4 and the UK
8.5.5. Line-wise Treated Cases of Peripheral T-cell lymphoma (PTCL) in EU4 and the UK
8.6. Japan
8.6.1. Total Incident cases of Peripheral T-cell lymphoma (PTCL) in Japan
8.6.2. Stage-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in Japan
8.6.3. Type-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in Japan
8.6.4. CD30 Expression-specific Incident Cases of Peripheral T-cell lymphoma (PTCL) in Japan
8.6.5. Line-wise Treated Cases of Peripheral T-cell lymphoma (PTCL) in Japan
9. Patient Journey of Peripheral T-cell lymphoma (PTCL)
10. Marketed Therapies
10.1. Marketed Competitive Landscape of PTCL
10.2. Valemetostat tosilate (EZHARMIA): Daiichi Sankyo
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Summary of Pivotal Trials
10.2.5. Analyst's View
10.3. Crizotinib (XALKORI): Pfizer
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental Activities
10.3.4. Summary of Pivotal Trials
10.3.5. Analyst's View
10.4. Tucidinostat (HIYASTA): HUYA Bioscience International (HUYABIO)
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Other Developmental Activities
10.4.4. Clinical Development
10.4.4.1. Clinical Trial Information
10.4.5. Summary of Pivotal Trials
10.4.6. Safety and Efficacy
10.4.7. Analyst's View
11. Emerging Therapies
11.1. Emerging Competitive Landscape of PTCL
11.2. Duvelisib (COPIKTRA): Secura Bio
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.3.1. Clinical Trial Information
11.2.4. Safety and Efficacy
11.2.5. Analyst Views
11.3. Lacutamab (IPH4102): Innate Pharma
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.3.1. Clinical Trial Information
11.3.4. Safety and Efficacy
11.3.5. Analyst Views
11.4. Linperlisib (YY-20394/ linprixetine): Shanghai YingLi Pharmaceutical
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.3.1. Clinical Trial Information
11.4.4. Safety and Efficacy
11.4.5. Analyst Views
11.5. KEYTRUDA: Merck
11.5.1. Product Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development
11.5.3.1. Clinical Trial Information
11.5.4. Safety and Efficacy
11.5.5. Analyst Views
11.6. OPDIVO: BMS
11.6.1. Product Description
11.6.2. Other Developmental Activities
11.6.3. Clinical Development
11.6.3.1. Clinical Trial Information
11.6.4. Safety and Efficacy
11.6.5. Analyst's Views
12. Peripheral T-cell lymphoma (PTCL): 7MM Analysis
12.1. Key Findings
12.2. Market Outlook of Peripheral T-cell lymphoma (PTCL)
12.3. Key Market Forecast Assumptions
12.3.1. Cost Assumptions
12.4. Conjoint Analysis of Peripheral T-cell lymphoma (PTCL)
12.5. Total Market Size of Peripheral T-cell lymphoma (PTCL) in the 7MM
12.6. Total Market Size of Peripheral T-cell lymphoma (PTCL) by Therapies in the 7MM
12.7. The United States
12.7.1. Total Market Size of Peripheral T-cell lymphoma (PTCL) in the United States
12.7.2. Total Market Size of Peripheral T-cell lymphoma (PTCL) by Therapies in the United States
12.8. EU4 and the UK
12.8.1. Total Market Size of Peripheral T-cell lymphoma (PTCL) in EU4 and the UK
12.8.2. Total Market Size of Peripheral T-cell lymphoma (PTCL) by Therapies in EU4 and the UK
12.9. Japan
12.9.1. Total Market Size of Peripheral T-cell lymphoma (PTCL) in Japan
12.9.2. Total Market Size of Peripheral T-cell lymphoma (PTCL) by Therapies in Japan
13. Unmet Needs of Peripheral T-cell lymphoma (PTCL)
14. SWOT Analysis of Peripheral T-cell lymphoma (PTCL)
15. KOL Views of Peripheral T-cell lymphoma (PTCL)
15.1. Expert/KOL Interview Highlights
16. Market Access and Reimbursement of Peripheral T-cell lymphoma (PTCL)
16.1. The United States
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. Japan
16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16.5. Market Access and Reimbursement of Peripheral T-cell lymphoma (PTCL) Therapies
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. Analyst's Capabilities
19. Disclaimer
20. About the Publisher
List of Tables [35]
List of Figures [35]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/f5df1h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.